Medical equipment maker Illumina announced on Wednesday its new series of smaller, low-cost benchtop gene sequencers, to make sequencing accessible to more research and testing labs.

Illumina is welcoming a new addition to its DNA sequencing lineup, with a pair of accessible benchtop instruments that incorporate the tech and chemistry used by its largest, top-of-the-line machines.

Illumina sequencing is renowned for its accuracy, high throughput, and robust infrastructure, while nanopore sequencing stands out for its long read lengths, real-time analysis, and portability.

Illumina aims to accelerate its current growth by expanding its core sequencing business, entering multiomics, and expanding its services, data, and software business to provide more complete ...

Thaysen described the company’s high-end sequencers, the NovaSeq X series, as integral to its growth; he expects revenue to reach high-single-digit percent growth by 2027.